Drug Approval | January 05, 2026
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
The approval is supported by data from three pivotal clinical trials
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
His professional background also includes key experience at Matrix Labs and Sun Pharma
Elanco expects Befrena to launch in the US in the first half of 2026
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Subscribe To Our Newsletter & Stay Updated
